This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

TK216 in Patients With Relapsed or Refractory Ewing Sarcoma

This study is currently recruiting participants.
See Contacts and Locations
Verified October 2016 by Oncternal Therapeutics, Inc
Information provided by (Responsible Party):
Oncternal Therapeutics, Inc Identifier:
First received: January 12, 2016
Last updated: October 13, 2016
Last verified: October 2016
Ewing sarcoma is characterized by genomic rearrangements resulting in over-expression of ets family transcription factors driving tumor progression. TK216 is designed to inhibit this effect by inhibiting downstream effects of the EWS-FLI1 transcription factor. This study is a first in human study of TK216 in subjects with Ewing sarcoma. The study is designed to establish initial safety and efficacy data to assess the potential of TK216 for further development.

Condition Intervention Phase
Sarcoma, Ewing Drug: TK216 Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Dose Escalation Study of Intravenous TK216 in Patients With Relapsed or Refractory Ewing Sarcoma

Resource links provided by NLM:

Further study details as provided by Oncternal Therapeutics, Inc:

Primary Outcome Measures:
  • Dose-limiting toxicities (DLTs) [ Time Frame: 18 months ]
    Listing of dose-limiting toxicities by daily dose in mg/m^2

  • Maximum tolerated dose (MTD) [ Time Frame: 18 months ]
    Maximum daily dose in mg/m^2

  • Biologically effective and recommended Phase 2 dose (RP2D) [ Time Frame: 18 months ]
    Daily dose in mg/m^2

Secondary Outcome Measures:
  • Adverse Events [ Time Frame: 18 months ]
  • Antitumor activity as measured by Overall Response Rate (ORR) [ Time Frame: 18 months ]
  • Antitumor activity as measured by Duration of Response (DOR) [ Time Frame: 18 months ]
  • Duration of Disease Control [ Time Frame: 18 months ]
  • Assay methods to detect EWS-FLI1 (or EWS-ERG and EWS-ets) [ Time Frame: 18 months ]
  • Pharmacokinetics: Maximum Plasma Concentration [Cmax] [ Time Frame: 18 months ]
  • Pharmacokinetics: Area Under the Curve [AUC] [ Time Frame: 18 months ]
  • Pharmacokinetics: Halflife [T1/2] [ Time Frame: 18 months ]
  • Pharmacodynamics: serum miRNA profile [ Time Frame: 18 months ]
  • Pharmacodynamics: tumor tissue RNA assays [ Time Frame: 18 months ]
  • Pharmacodynamics: tumor tissue protein assays [ Time Frame: 18 months ]

Estimated Enrollment: 45
Study Start Date: May 2016
Estimated Study Completion Date: June 2018
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: TK216 treatment
Dose escalation and expansion cohorts to determine dose-limiting toxicities, maximally tolerated dose, preliminary efficacy, and recommended phase 2 dose.
Drug: TK216
Inhibitor of protein-protein interactions of EWS-FLI1 fusion protein


Ages Eligible for Study:   12 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed diagnosis of Ewing sarcoma (including ESFT) in subjects with relapsed or refractory disease who have failed standard therapy

Exclusion Criteria:

  • Symptomatic brain metastases
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02657005

Contact: Tilman Oltersdorf, MD 760 274 5789
Contact: Deborah Jezior

United States, California
UCLA Jonsson Comprehensive Cancer Center Recruiting
Los Angeles, California, United States, 90095
Contact: Joanna Balducci    310-206-2632      
Principal Investigator: Noah Federman, MD         
United States, New York
Memorial Sloan Kettering Cancer Center Recruiting
New York, New York, United States, 10174
Contact: Dara Herman    646-888-5729   
Contact: BB Chamberlain    646 888 5711   
Principal Investigator: Paul A Meyers, MD         
United States, Texas
UT MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Joseph A Ludwig, MD    713-792-3626      
Principal Investigator: Joseph A Ludwig, MD         
Sponsors and Collaborators
Oncternal Therapeutics, Inc
Study Director: James Breitmeyer, MD Oncternal Therapeutics
  More Information

Responsible Party: Oncternal Therapeutics, Inc Identifier: NCT02657005     History of Changes
Other Study ID Numbers: TK216-01
Study First Received: January 12, 2016
Last Updated: October 13, 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Sarcoma, Ewing
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms, Bone Tissue
Neoplasms, Connective Tissue processed this record on August 18, 2017